Market news

Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.

Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.

Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Recent price strength puts OptimumBank, EuroDry, Enova International, Anika Therapeutics and GEO in focus as August stocks with momentum.

Detailed price information for Anika Therapeutics (ANIK-Q) from The Globe and Mail including charting and trades.

Detailed price information for Anika Therapeutics (ANIK-Q) from The Globe and Mail including charting and trades.

The latest analyst update on Anika Therapeutics centers on a higher price target, with modeled fair value moving from US$16 to US$21 per share. Research commentary describes this shift as a reflection of greater confidence in the company’s ability to sustain profitability, supported by the recent Q2 beat, stronger margins, and raised guidance. As you read on, you will see how this evolving narrative is taking shape and what to watch to stay in step with it. Stay updated as the Fair Value for...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Commercial Channel Revenue Increased 17% to a Record $13.9 Million Delivered $3.3 Million of Net Income, 65% Gross Margin, and $7.1 Million of Adjusted EBITDA, Highest Since 2020 Raising Full-Year 2026 Financial Guidance and Revising 2027 Revenue Forecast BEDFORD, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early-intervention orthopedics, today announced

Anika Therapeutics Inc (ANIK) reports robust growth in commercial and international channels, while navigating pricing pressures and regulatory uncertainties.

Anika Therapeutics (NASDAQ:ANIK) reported higher second-quarter revenue, expanded gross margin and its strongest adjusted EBITDA performance since 2020, as international commercial growth and manufacturing improvements supported profitability. Total revenue rose 16% year over year to $32.6 million

Moby summary of Anika Therapeutics, Inc.'s Q2 2026 earnings call

Detailed price information for Anika Therapeutics (ANIK-Q) from The Globe and Mail including charting and trades.

BEDFORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2026 financial results before the opening of the market on Wednesday, July 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (int